Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Cash & Current Investments: 2018-2024

Historic Cash & Current Investments for Revolution Medicines (RVMD) over the last 7 years, with Dec 2024 value amounting to $2.3 billion.

  • Revolution Medicines' Cash & Current Investments rose 24.66% to $1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 billion, marking a year-over-year increase of 26.34%. This contributed to the annual value of $2.3 billion for FY2024, which is 23.55% up from last year.
  • As of FY2024, Revolution Medicines' Cash & Current Investments stood at $2.3 billion, which was up 23.55% from $1.9 billion recorded in FY2023.
  • Revolution Medicines' Cash & Current Investments' 5-year high stood at $2.3 billion during FY2024, with a 5-year trough of $440.7 million in FY2020.
  • For the 3-year period, Revolution Medicines' Cash & Current Investments averaged around $1.6 billion, with its median value being $1.9 billion (2023).
  • Data for Revolution Medicines' Cash & Current Investments shows a peak YoY soared of 259.03% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Revolution Medicines' Cash & Current Investments stood at $440.7 million in 2020, then spiked by 30.93% to $577.1 million in 2021, then climbed by 11.76% to $644.9 million in 2022, then spiked by 187.31% to $1.9 billion in 2023, then grew by 23.55% to $2.3 billion in 2024.